Bristol Myers breast cancer drug cuts progression risk
Bristol Myers Squibb and SystImmune announced their experimental drug izalontamab brengitecan significantly slowed advanced breast cancer progression in a late-stage study. The antibody-drug conjugate reduced the risk of disease worsening or death by 59 percent compared to standard chemotherapy.
Xurve View
Insights:
Xurve View
Bristol-Myers Squibb Co and partner SystImmune reported their breast cancer drug cut disease progression risk by 59% in a late-stage study. The trial enrolled 383 patients with advanced hormone-receptor-positive, HER2-negative breast cancer. The data strengthens the market position for the up to $8.4 billion partnership signed in 2023.
